Lipoprotein-associated phospholipase A2 and cardiovascular risk -: State of the evidence and future directions

被引：15

作者：

Iribarren, C ^{[1
]}

机构：

[1] No Calif Kaiser Permanente, Div Res, Oakland, CA USA

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2006年 / 26卷 / 01期

关键词：

D O I：

10.1161/01.ATV.0000196545.32393.13

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：5 / 6

页数：2

共 17 条

[1] The effect of statin therapy on lipoprotein associated phospholipase A2 levels [J].

Albert, MA ;

Glynn, RJ ;

Wolfert, RL ;

Ridker, PM .

ATHEROSCLEROSIS, 2005, 182 (01) :193-198

[2] Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].

Ballantyne, CM ;

Hoogeveen, RC ;

Bang, H ;

Coresh, P ;

Folsom, AR ;

Chambless, LE ;

Myerson, M ;

Wu, KK ;

Sharrett, AR ;

Boerwinkle, E .

ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (21) :2479-2484

[3] Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].

Ballantyne, CM ;

Hoogeveen, RC ;

Bang, H ;

Coresh, J ;

Folsom, AR ;

Heiss, G ;

Sharrett, AR .

CIRCULATION, 2004, 109 (07) :837-842

[4] The identification of clinical candidate SB-480848:: A potent inhibitor of lipoprotein-associated phospholipase A2 [J].

Blackie, JA ;

Bloomer, JC ;

Brown, MJB ;

Cheng, HY ;

Hammond, B ;

Hickey, DMB ;

Ife, RJ ;

Leach, CA ;

Lewis, VA ;

Macphee, CH ;

Milliner, KJ ;

Moores, KE ;

Pinto, IL ;

Smith, SA ;

Stansfield, IG ;

Stanway, SJ ;

Taylor, MA ;

Theobald, CJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (06) :1067-1070

[5] A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].

Blake, GJ ;

Dada, N ;

Fox, JC ;

Manson, JE ;

Ridker, PM .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306

[6] Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].

Brilakis, ES ;

McConnell, JP ;

Lennon, RJ ;

Elesber, AA ;

Meyer, JG ;

Berger, PB .

EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144

[7] Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma [J].

Gazi, I ;

Lourida, ES ;

Filippatos, T ;

Tsimihodimos, V ;

Elisaf, M ;

Tselepis, AD .

CLINICAL CHEMISTRY, 2005, 51 (12) :2264-2273

[8] Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults -: The CARDIA study [J].

Iribarren, C ;

Gross, MD ;

Darbinian, JA ;

Jacobs, DR ;

Sidney, S ;

Loria, CM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (01) :216-221

[9]

JOHNSON A, CIRCULATION S3, V110, P590

[10] Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population -: Results from the 14-year follow-up of a large cohort from southern Germany [J].

Koenig, W ;

Khuseyinova, N ;

Löwel, H ;

Trischler, G ;

Meisinger, C .

CIRCULATION, 2004, 110 (14) :1903-1908

← 1 2 →